This phase III trial is evaluating an immunotherapy (tabelecleucel) for the treatment of Epstein-Barr Virus-associated post-transplant lymphoproliferative disease in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
This trial is treating patients with Epstein-Barr Virus-associated post-transplant lymphoproliferative disease.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab
This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr Virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab
Recruiting Hospitals Read More